| 3.1 Smoking cessation |
5 |
1447 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.94 [1.21, 3.13] |
| 3.2 Adverse events |
5 |
840 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.91, 1.11] |
| 3.2.1 1 week |
1 |
48 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.50 [0.27, 8.19] |
| 3.2.2 8 weeks |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.18 [0.38, 3.66] |
| 3.2.3 12 weeks |
1 |
255 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.01 [0.94, 1.08] |
| 3.2.4 6 months |
2 |
513 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.97 [0.71, 1.34] |
| 3.3 Serious adverse events |
8 |
1272 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.56, 1.79] |
| 3.3.1 1 week |
1 |
48 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 3.3.2 4 weeks |
1 |
74 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 3.3.3 8 weeks |
1 |
24 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.50 [0.16, 78.19] |
| 3.3.4 6 months |
4 |
1009 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.95 [0.52, 1.72] |
| 3.3.5 1 year |
1 |
117 |
Risk Ratio (M‐H, Fixed, 95% CI) |
Not estimable |
| 3.4 Carbon monoxide (ppm) |
5 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.4.1 Change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.4.2 Absolute values at follow‐up |
4 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.5 Heart rate |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.5.1 Absolute values at follow‐up |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.6 Systolic blood pressure |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.6.1 Absolute values at follow‐up |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.7 FeNO (ppb) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.7.1 Change from baseline |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.8 FEV1 (l) |
1 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.8.1 Absolute values at follow‐up |
1 |
|
Std. Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.9 FEV1/FVC |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.9.1 Absolute values at follow‐up |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 3.10 NNAL (pmol/mg creatinine) |
2 |
363 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.02 [‐0.45, 0.41] |
| 3.10.1 Change from baseline |
1 |
148 |
Mean Difference (IV, Fixed, 95% CI) |
15.27 [‐4.98, 35.52] |
| 3.10.2 Absolute values at follow‐up |
1 |
215 |
Mean Difference (IV, Fixed, 95% CI) |
‐0.03 [‐0.46, 0.40] |
| 3.11 Product use at 6+ months |
3 |
874 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.15 [0.94, 1.41] |
